Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients

Author： Al-Dasooqi Noor   Bowen Joanne   Gibson Rachel   Sullivan Thomas   Lees Jude   Keefe Dorothy  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.27, Iss.2, 2009-04, pp. : 173-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

By  

Current Cancer Drug Targets, Vol. 15, Iss. 8, 2015-01 ,pp. : 665-683

Bentham Science Publishers

Access to resources Recommend Favorite

First-line therapy with trastuzumab plus paclitaxel and carboplatin may be active in patients with HER-2 over-expressing metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

By  

Current Drug Targets, Vol. 14, Iss. 8, 2013-07 ,pp. : 889-898

Bentham Science Publishers

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite